Device autonomic regulation therapy in patients with heart failure and reduced ejection fraction

Noah N. Williford, Giselle Statz, Douglas L. Mann, Brian Olshansky

Research output: Contribution to journalArticlepeer-review


Heart failure with reduced ejection fraction (HFrEF) is a common, incompletely treatable, complex, progressive, and severe medical problem despite guideline-directed medical therapy. HFrEF is associated with sympathetic activation and parasympathetic inhibition; these reflexive processes may ultimately be maladaptive and exacerbate or even perpetuate the problem. Attempts to regulate autonomic tone during HFrEF in animal models and in humans has shown promise with beneficial effects that include improvement in symptoms, mitigation of arrhythmic events, reduction in mortality, and correction in hemodynamics. Several modalities to regulate autonomic tone such as unilateral parasympathetic nerve activation, baroreceptor activation, renal nerve ablation and spinal cord stimulation have been investigated. Although they demonstrated some benefit, the long-term efficacy in HFrEF has not been proven. Considering specific limitations of each modality, to draw definitive conclusions is impossible at this time. Here, we review the present state-of-the-art literature? of device of autonomic regulation therapy to affect outcomes in HFrEF.

Original languageEnglish
JournalJournal of Atrial Fibrillation
Issue number1
StatePublished - Jul 2020


  • Autonomic Nervous System
  • Heart Failure


Dive into the research topics of 'Device autonomic regulation therapy in patients with heart failure and reduced ejection fraction'. Together they form a unique fingerprint.

Cite this